By Counterforce Health Team in Evkeeza (evinacumab-dgnb) —

How to Get Evkeeza (evinacumab-dgnb) Covered by Blue Cross Blue Shield Michigan: Appeals Guide & Forms

Quick Answer: Getting Evkeeza Covered by Blue Cross Blue Shield Michigan

To get Evkeeza (evinacumab-dgnb) covered by BCBS Michigan for homozygous familial hypercholesterolemia (HoFH), you'll need prior authorization with genetic testing confirmation, documented LDL-C levels ≥400 mg/dL, and evidence of inadequate response to maximum tolerated lipid-lowering therapies. If denied, appeal within BCBS's internal process first, then file for Michigan DIFS external review within 127 days. Start by having your doctor submit a prior authorization request through the BCBS provider portal or CoverMyMeds, including complete HoFH documentation and medical necessity justification.

Table of Contents

  1. Understanding Your Denial
  2. Common Denial Reasons & Quick Fixes
  3. Prior Authorization Requirements
  4. First-Level Internal Appeal
  5. Peer-to-Peer Review Strategy
  6. Michigan DIFS External Review
  7. Appeal Letter Templates
  8. Cost Assistance Programs
  9. When to Escalate
  10. Frequently Asked Questions

Understanding Your Denial

When BCBS Michigan denies Evkeeza coverage, your denial letter will include specific reason codes. The most common reasons for this ultra-rare disease medication include:

  • Missing HoFH genetic confirmation - Requires bi-allelic pathogenic variants in LDLR, APOB, PCSK9, or LDLRAP1 genes
  • Insufficient background therapy documentation - Must show trials of maximum tolerated statin, ezetimibe, and PCSK9 inhibitor (unless contraindicated)
  • Missing recent LDL-C levels - Typically need levels ≥400 mg/dL documented within the past 3-6 months
  • Step therapy requirements - May require documented failure of other HoFH treatments first
Note: Evkeeza is approved by the FDA for HoFH patients aged 5 years and older as of 2024, with recent expansion to include children aged 1-4 years.

Common Denial Reasons & Quick Fixes

Denial Reason Required Documentation How to Submit
No genetic testing Genetic test results showing HoFH variants Submit via provider portal with lab report
LDL-C levels missing Recent lipid panel (≤90 days) showing ≥400 mg/dL Include with prior auth resubmission
Background therapy incomplete Documentation of statin, ezetimibe, PCSK9 inhibitor trials Provide treatment history with dates and outcomes
Medical necessity unclear Physician letter explaining cardiovascular risk Submit comprehensive medical necessity letter

Prior Authorization Requirements

BCBS Michigan requires prior authorization for Evkeeza through their specialty pharmacy benefit. Your prescriber must submit documentation including:

Required Clinical Documentation

  • Confirmed HoFH diagnosis with genetic testing results
  • Baseline LDL-C levels ≥400 mg/dL (untreated) or current levels on maximum therapy
  • Prior therapy documentation showing inadequate response to:
    • High-intensity statin (unless contraindicated)
    • Ezetimibe
    • PCSK9 inhibitor (evolocumab or alirocumab)
    • LDL apheresis consideration (if appropriate)
  • Patient weight for dosing calculation (15 mg/kg every 4 weeks)
  • Cardiovascular risk assessment and treatment goals

Submission Process

Providers can submit prior authorization requests through:

  • BCBS Michigan provider portal (primary method)
  • CoverMyMeds electronic platform
  • Fax: 1-866-601-4425 for general pharmacy requests
  • Phone: 1-800-437-3803 for questions

Counterforce Health specializes in helping patients navigate complex prior authorization processes for rare disease medications like Evkeeza. Their platform can help identify the specific denial basis and draft targeted appeals using payer-specific criteria and evidence-based medical necessity arguments.

First-Level Internal Appeal

If your initial prior authorization is denied, you have the right to file an internal appeal with BCBS Michigan. This is your first formal opportunity to challenge the denial.

Timeline and Process

  • Deadline: 60 days from denial notice for commercial plans
  • Expedited appeals: Available if delay could seriously jeopardize health
  • Review period: BCBS has 30 days for standard appeals, 72 hours for expedited

Required Components for Appeal

  1. Completed appeal form (available on BCBS Michigan website)
  2. Original denial letter
  3. Updated medical necessity letter addressing specific denial reasons
  4. Supporting clinical evidence:
    • Peer-reviewed studies on Evkeeza efficacy in HoFH
    • FDA prescribing information
    • Professional guidelines (ACC/AHA, NLA)
    • Patient-specific clinical data

Medical Necessity Letter Checklist

Your physician's appeal letter should include:

  • HoFH diagnosis confirmation with genetic testing details
  • Current LDL-C levels and cardiovascular risk
  • Documented inadequate response to conventional therapies
  • Contraindications to alternative treatments (if applicable)
  • Expected clinical benefits of Evkeeza therapy
  • Monitoring plan and treatment goals

Peer-to-Peer Review Strategy

If your written appeal is unsuccessful, request a peer-to-peer review where your physician can speak directly with a BCBS medical director.

Scheduling the Call

  • Request through: BCBS provider services or utilization management
  • Timeline: Usually scheduled within 1-2 business days
  • Duration: Typically 15-20 minutes

Preparation Tips

Your physician should prepare:

  • Patient summary: Age, HoFH genotype, family history, cardiovascular events
  • Treatment history: Specific medications tried, doses, duration, and outcomes
  • Clinical rationale: Why Evkeeza is medically necessary for this specific patient
  • Guidelines support: Reference FDA approval and professional society recommendations

Michigan DIFS External Review

If BCBS Michigan upholds their denial after internal appeals, you can request an external review through the Michigan Department of Insurance and Financial Services (DIFS).

External Review Process

  • Deadline: 127 days from final internal denial
  • Cost: No fee for patients
  • Timeline: 60 days maximum for standard review, 72 hours for expedited
  • Decision: Binding on BCBS Michigan

How to File

Contact DIFS:

  • Phone: 877-999-6442 (Monday-Friday, 8 AM-5 PM)
  • Mail: DIFS Appeals Section, PO Box 30220, Lansing, MI 48909-7720
  • Online: Through DIFS External Review Portal

Required Documentation:

  • Final denial letter from BCBS Michigan
  • Your insurance policy information
  • Complete medical records supporting Evkeeza request
  • Physician letter of medical necessity
  • For expedited review: physician letter documenting urgency

Appeal Letter Templates

Patient Phone Script for BCBS Michigan

"Hi, I'm calling about a prior authorization denial for Evkeeza for my homozygous familial hypercholesterolemia. My member ID is [ID]. I'd like to understand the specific denial reasons and start the appeal process. Can you transfer me to utilization management and provide the appeal form?"

Medical Necessity Letter Framework

Opening: "I am writing to request coverage for Evkeeza (evinacumab-dgnb) for my patient [Name] with confirmed homozygous familial hypercholesterolemia (HoFH)."

Diagnosis: "Genetic testing confirms bi-allelic pathogenic variants in [specific gene], consistent with HoFH diagnosis. Current LDL-C level is [value] mg/dL despite maximum tolerated lipid-lowering therapy."

Prior Therapies: "The patient has had inadequate response to [list specific medications with doses and duration]. [Describe any contraindications or adverse effects]."

Medical Necessity: "Evkeeza represents the standard of care for HoFH patients who have not achieved adequate LDL-C reduction with conventional therapies, as supported by FDA approval and clinical trial data showing up to 50% LDL-C reduction."

Closing: "Given the patient's extremely high cardiovascular risk and inadequate response to available alternatives, Evkeeza is medically necessary to prevent premature cardiovascular events."

Cost Assistance Programs

While pursuing insurance coverage, explore these financial assistance options:

Manufacturer Support

  • Regeneron Patient Assistance Program - Income-based assistance for eligible patients
  • Evkeeza Copay Program - May reduce out-of-pocket costs for commercially insured patients

Additional Resources

  • Patient Advocate Foundation - Helps with insurance appeals and financial assistance
  • National Organization for Rare Disorders (NORD) - Rare disease patient assistance programs
  • Good Days - Chronic disease financial assistance foundation

When to Escalate

Consider escalating your case if:

  • Multiple internal appeals have been denied
  • BCBS is not following their own medical policies
  • Delays are causing harm to patient health
  • You suspect discriminatory practices

Michigan Insurance Regulators

Michigan Department of Insurance and Financial Services (DIFS)

  • Consumer Hotline: 877-999-6442
  • Online Complaints: Through DIFS website
  • Email: Available through official DIFS contact forms

Frequently Asked Questions

How long does BCBS Michigan prior authorization take? Standard prior authorizations typically take 5-10 business days. Expedited requests (when delay could harm patient health) are processed within 72 hours.

What if Evkeeza is non-formulary on my BCBS Michigan plan? You can request a formulary exception. Your doctor must provide clinical justification for why formulary alternatives are inappropriate or ineffective.

Can I request an expedited appeal? Yes, if waiting for the standard appeal timeline could seriously jeopardize your health. Your physician must provide a supporting letter documenting the urgency.

Does step therapy apply if I've tried other HoFH treatments outside Michigan? Yes, prior therapy documentation from other states is typically accepted. Provide complete records showing medication names, doses, duration, and outcomes.

What happens if the external review is denied? You may seek judicial review in Michigan circuit court within 60 days of the DIFS decision, though this is rare and typically requires legal counsel.

How much does Evkeeza cost without insurance? The manufacturer-stated average wholesale cost is approximately $450,000 per year, though actual costs vary based on patient weight and dosing requirements.

About Counterforce Health: Counterforce Health helps patients, clinicians, and specialty pharmacies get prescription drugs approved by turning insurance denials into targeted, evidence-backed appeals. The platform specializes in complex prior authorization processes for rare disease medications, identifying denial reasons and drafting point-by-point rebuttals aligned to each payer's specific policies and medical criteria.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Always consult with your healthcare provider and insurance plan for specific coverage decisions. Coverage policies and procedures may change; verify current requirements with BCBS Michigan and Michigan DIFS.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.